VASILIP

This brand name is authorized in Albania, Estonia, Croatia, Lithuania, Poland, Romania

Active ingredients

The drug VASILIP contains one active pharmaceutical ingredient (API):

1 Simvastatin UNII AGG2FN16EV - SIMVASTATIN

Simvastatin has a potent activity in inhibiting HMG-CoA reductase (3-hydroxy–3-ethylglutaryl-CoA-reductase). Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations. Read about Simvastatin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AA01	Simvastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AL	Fondi i Sigurimit të Detyrueshëm të Kujdesit Shëndetësor	Identifier(s): 350/73
Country: EE	Ravimiamet	Identifier(s): 1010260, 1010271, 1086218, 1594447, 1594458, 1594469
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-766497006, HR-H-862193542, HR-H-967939300
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1006196, 1006197, 1007629
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100105641, 100105658, 100112500
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W08479001, W08725001, W13137001